Safety alert against LeadCare Testing Systems by Magellan Diagnostics due to inaccurate test results

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results for some children and adults in the United States. Falsely lower test results may lead to improper patient management and treatment for lead exposure or poisoning.

The FDA is unable to identify the root cause for the inaccurate results, based on data provided by Magellan. We are conducting studies with the CDC to identify the cause and better characterize the extent of the problem. At this time, the FDA has no evidence that Magellan’s LeadCare Testing Systems have the same problem when processing capillary blood samples. The FDA is aggressively investigating the root cause of this issue with the manufacturers, health care facilities and the CDC, and will update this safety communication as critical information becomes available.  For more information please refer to the Safety Communication.

BACKGROUND: Magellan Diagnostics Inc. manufactures the following lead testing systems affected by this warning: LeadCare, LeadCare II, LeadCare Plus, and LeadCare Ultra.

The LeadCare Testing Systems detect the amount of lead in a blood sample obtained from finger or heel prick (capillary) or from a vein (venous). This warning applies to all four Magellan Diagnostics LeadCare Testing Systems when processing venous blood samples, in the United States.

Note: Magellan's LeadCare II is a point-of-care (CLIA-waived) blood lead testing system on which users mostly test capillary blood samples. However, some laboratories also process venous blood samples with the LeadCare II system, which is why this safety communication includes all Magellan LeadCare Testing Systems.

The LeadCare Testing Systems are used in clinical laboratories,...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Potassium Phosphate and Succinylcholine Chloride by Advanced Pharma - Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Venture catheters by Vascular Solutions- Catheter tip may split or separate during use

Read more
  • MedWatch Drug Updates
  • 1 comment

Drug safety alert: Canagliflozin (Invokana, Invokamet) may increase the risk of leg and foot amputations

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Radicava (edaravone) for amyotrophic lateral sclerosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Use of Medtronic’s NavLock Tracker with non-Medtronic instruments can cause spinal injury or death

Read more
  • FDA Drug Updates
  • no comment

FDA approved Rydapt (midostaurin) for acute myeloid leukemia

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Stivarga (regorafinib) for liver cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Brineura (cerliponase alfa) for Batten disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of 25% Dextrose Injection, USP, (Infant) by Hospira- Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of SpF PLUS-Mini and SpF XL IIb Implantable Spinal Fusion Stimulators by Zimmer Biomet

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Mibela 24 Fe chewable tablet by Lupin Pharmaceuticals Inc- Packaging error affecting dosing regimen

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ingrezza (valbenazine) for tardive dyskinesia

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of physician sample of Brilinta (ticagrelor) 90mg by AstraZeneca- Presence of another medicine Zurampic

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Ocrevus (ocrelizumab) for multiple sclerosis

Read more
  • FDA Drug Updates
  • no comment

FDA approved Zejula (niraparib) for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Dupixent (dupilumab) for atopic dermatitis

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of HeartMate II LVAS Pocket System Controller by Abbott-Thoratec- Controller malfunction after exchange

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Tri-Ton by Dynamic Technical Formulations LLC- Presence of unapproved drug andarine and ostarine

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of V60 Non-invasive ventilator by Respironics- Unexpected stop in ventilation therapy

Read more
  • MedWatch Drug Updates
  • 1 comment

Gadolinium-based contrast agent for MRI- No adverse effects reported with gadolinium retention in the brain

Read more
  • FDA Drug Updates
  • no comment

FDA approved Bavencio (avelumab) for Merkel cell carcinoma

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xadago (safinamide) for Parkinson’s disease

Read more